|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, because of low or absent coxsackievirus and adenovirus receptor levels on the surface of many kinds of tumor cells, the efficiency of adenovirus infection of target tumor cells may be low.
|
28407709 |
2020 |
|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, adenovirus infection and/or the maternal immune response to adenovirus infection induced the death of placental cell types that expressed CAR.
|
11207218 |
2001 |
|
Adenovirus Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, the PDZ1 domain is able to rescue CAR(Ex8) and adenovirus infection from MAGI-1-mediated suppression.
|
22718816 |
2012 |
|
Adenovirus Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
These data reinforce the importance of CAR<sup>Ex8</sup> in apical adenovirus infection and provide a new model cell line to probe isoform specific biological functions of CAR.
|
31394408 |
2019 |
|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Susceptibility of prostate cancer cells LNCaP, PC3, and DU145 to adenovirus infection was associated with CAR expression.
|
26799485 |
2016 |
|
Adenovirus Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that cigarette smoke exposure increases epithelial susceptibility to adenovirus infection by increasing the abundance of apical CAR.
|
23166798 |
2012 |
|
Adenovirus Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, although a cell type may be resistant to adenovirus infection, it is impossible to know whether it is due to a deficiency, as both CAR absence and inaccessibility are barriers to adenovirus-mediated gene transfer.
|
21918008 |
2012 |
|
Adenovirus Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Adenoviruses are common pathogens.The localization of their receptors coxsackievirus and adenovirus receptor, and desmoglein-2 in cell-cell junction complexes between polarized epithelial cells represents a major challenge for adenovirus infection from the apical surface.
|
25723153 |
2015 |
|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of an engineered soluble coxsackievirus and adenovirus receptor by a dimeric AAV9 vector inhibits adenovirus infection in mice.
|
25786873 |
2015 |
|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data show that the expression of CAR is closely related to susceptibility to adenovirus infection in human ovarian cancer cells.
|
11972385 |
2002 |
|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FACS analysis and adenovirus infection assay revealed that there was a good correlation between the level of CAR expression and the transfection efficiency.
|
12529974 |
2003 |
|
Adenovirus Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This may indicate that CAR expression contributes to the efficacy of adenovirus infection and the antitumor activity of telomelysin in early stages of treatment.
|
20043095 |
2010 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As for CAR4/6 expression levels of CAR6/7 were significantly lower in normal tissue as compared with CIN2/3 and cancer (p < 0.01).
|
21431326 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This is because checkpoint molecules, adoptive specific lymphocyte transfer and chimeric antigen T-cell (CAR-T) therapy are able to induce more durable responses in an increasing number of malignancies compared to chemotherapy.
|
28974121 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Also, a potent cancer chemotherapeutic agent (FR901228), a histone deacetylase inhibitor, was able to induce endogenous CAR gene expression in several urogenital cancer cells.
|
14695181 |
2003 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials.
|
28128714 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the administrations of immune checkpoint modulators (represented by anti-CTLA4 and anti-PD antibodies) and adoptive immune cells (represented by CAR-T) have exhibited unexpected antitumor effect in multiple types of cancer, bringing a new era for cancer therapy.
|
31730903 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vaccines or T cells modified with a chimeric antigen receptor (CAR-T cells) could also play a role in the treatment of cancer in the future.
|
30638624 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens by transferring chimeric antigen receptor (CAR) genes is becoming an effective strategy to combat cancer.
|
31004624 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T cells have produced clinical responses in B-cell malignancies that are otherwise refractory to conventional therapies.
|
30593467 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor-modified T cells (CAR-T) have emerged as a new modality for cancer immunotherapy due to their potent efficacy against terminal cancers.
|
26895243 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR NK-92 cells can be produced at much lower cost compared to CAR T cells, and we believe after being optimized, they will be widely accessible for the treatment of cancer.
|
30034945 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T-cell (CAR-T) therapy is a promising new class of cancer therapy but has a high up-front cost.
|
30551196 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-killing CAR therapies gain speed.
|
25583785 |
2015 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using optimized electroporation voltage, interleukin-15 alone and co-culturing CAR T cells with peripheral blood mononuclear cells, we were able to expand CAR19 T-cell cultures by up to 765-fold over 3 weeks in normal donors and 180-fold in patients with B-cell malignancies.
|
26212611 |
2015 |